Mark Bach
Chief Tech/Sci/R&D Officer chez STRUCTURE THERAPEUTICS INC.
Fortune : 61 712 $ au 31/03/2024
Profil
Le Dr Mark A. Bach, MD, est vice-président principal chargé du développement clinique chez Ascendis Pharma A/S. Auparavant, le Dr Bach a occupé les postes de directeur général chez Accumulus Synergy, Inc, de responsable des sciences médicales pour la région Asie-Pacifique chez Janssen Pharmaceuticals, Inc, de vice-président de la recherche et du développement chez Janssen Pharmaceutical KK, et de vice-président des opérations de recherche clinique au niveau mondial chez Merck & Co, Inc. Il a obtenu son diplôme de premier cycle au Carleton College, un doctorat à l'Université de Chicago et un doctorat au Baylor College of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/03/2024 | 4 320 ( 0,00% ) | 61 712 $ | 31/03/2024 |
Postes actifs de Mark Bach
| Sociétés | Poste | Début |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01/06/2021 |
Anciens postes connus de Mark Bach
| Sociétés | Poste | Fin |
|---|---|---|
| Accumulus Synergy, Inc | Chief Executive Officer | 01/10/2020 |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | 01/08/2019 |
Janssen Pharmaceutical KK
 Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Chief Tech/Sci/R&D Officer | 01/11/2012 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2010 |
| ASCENDIS PHARMA A/S | Chief Tech/Sci/R&D Officer | - |
Formation de Mark Bach
| Carleton College | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
| Baylor College of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| STRUCTURE THERAPEUTICS INC. | Commercial Services |
| Entreprise privées | 3 |
|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Janssen Pharmaceutical KK
Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Health Technology |
| Accumulus Synergy, Inc |
